Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Autor: Kathryn Pritchard-Jones, Anne-Sophie DEFACHELLES, Sucheta Vaidya, Gustaf Ljungman, Norbert Graf, Marc Ansari, Gordan Vujanic, Ricardo López Almaraz, Pedro Zubizarreta, Jan Godziński, Pamela Kearns, Anna Llort, Beatriz De Camargo, Leo Kager, Harm Van Tinteren, Ingrid Øra

Publikováno v: Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, M M, Acha, T, Godzinski, J, Oldenburger, F, Boccon-Gibod, L, Leuschner, I, Vujanic, G, Sandstedt, B, de Kraker, J, van Tinteren, H, Graf, N & SIOP Renal Tumours Study Group 2015, ' Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001) : an open-label, non-inferiority, randomised controlled trial ', Lancet, vol. 386, no. 9999, pp. 1156-1164 . https://doi.org/10.1016/S0140-6736(14)62395-3
Lancet, 386(9999), 1156-1164. Elsevier Limited
The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64

BACKGROUND: Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05386b33380bcd2146bacb31bab8c77a
https://doi.org/10.1016/s0140-6736(14)62395-3

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Autor: Urs Hess, Jean-Pierre Marolleau, Patrice Chevallier, Kheira Beldjord, Martine Escoffre-Barbe, Sylvie Chevret, Norbert Ifrah, Véronique Lhéritier, Thorsten Braun, Norbert Vey, Dominik Heim, Marie C. Béné, Mathilde Hunault, Nicolas Boissel, Xavier Thomas, Jean-Yves Cahn, Françoise Huguet, Thibaut Leguay, Jean-Michel Pignon, Sébastien Maury, Yves Chalandon, Hervé Dombret

Publikováno v: New England Journal of Medicine, Vol. 375, No 11 (2016) pp. 1044-1053
New England Journal of Medicine
New England Journal of Medicine, 2016, 375, pp.1044--1053. 〈10.1056/NEJMoa1605085〉
New England Journal of Medicine, 2016, 375, pp.1044--1053. ⟨10.1056/NEJMoa1605085⟩
New England Journal of Medicine, Massachusetts Medical Society, 2016, 375, pp.1044--1053. ⟨10.1056/NEJMoa1605085⟩

International audience; Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although si

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40515bf4eabc74dfa370eb4fdc45428d
https://archive-ouverte.unige.ch/unige:99092

Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

Autor: Briassoulis, E. Ch, Samantas, E., Kalofonos, H. P., Skarlos, Dimosthenis V., Makatsoris, T., Christodoulou, C., Fountzilas, George, Bamias, A. T., Dimopoulos, M. A., Kosmidis, Paraskevas A., Pavlidis, Nicholas

Publikováno v: Cancer chemotherapy and pharmacology

AIM: The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. METHODS: Successive coh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2618c16a6a2974616324845805afa
https://doi.org/10.1007/s00280-004-0994-8

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Autor: Joseph C. Carmichael, G. Gruia, P. Jandik, Timothy Iveson, Philippe Rougier, Lucile Awad, M. Alakl, Arnaud Roth, P. Karasek, Roger D James, David Cunningham, Jean-Yves Douillard, M. Navarro

Publikováno v: The Lancet, Vol. 355, No 9209 (2000) pp. 1041-7

Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.387 patients previously untreat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f7b0deddb3efed185600f8daaa4459
https://doi.org/10.1016/s0140-6736(00)02034-1

Combined concomitant boost radiotherapy and chemotherapy in stage III–IV head and neck carcinomas: A comparison of toxicity and treatment results with those observed after radiotherapy alone

Autor: Pavel Dulguerov, Willy Lehmann, Raymond Miralbell, Abdelkarim S. Allal, A Bardina, Sabine Bieri, John M. Kurtz

Publikováno v: Annals of Oncology, Vol. 8, No 7 (1997) pp. 681-4

Background Alteration of radiation therapy (RT) fractionation and the combination of chemotherapy (CT) with RT represent two predominant fields of current research in the treatment of head and neck carcinomas. To assess the potential integration of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdab4b548265857a5bf51e38a965ed4b
https://doi.org/10.1023/a:1008260720076